The world's first seed cell to use iNSC for stem cell therapy for neurological diseases；

The world's first researcher to complete iNSC-DAP Parkinson's cell therapy initiated a clinical trial (IIT) for one year of follow-up, with positive results； Pursuing safe, long-lasting new stem cell therapies for neurological diseases

Wiseheart MedVal Biotech Co., Ltd. was established in July 2021. Prior to this, our scientists had been deeply involved in research in the field of stem cell regenerative medicine treatment for more than ten years. We are committed to applying internationally leading cell reprogramming technology and gene therapy technology with independent intellectual property rights to drug research on neurological diseases and the development of innovative therapies.

At present, we have established three core technology platforms, namely the cell reprogramming platform, the induced neural stem cell (iNSCs) differentiation platform, and the organoid differentiation platform. Based on these three major technology platforms, we will open up the future of innovative treatments for neurological diseases. The first innovative drug under development uses induced neural stem cells (iNSCs) to differentiate into dopaminergic neural precursor cells (iNSC-DAP), which can be injected intracranially to precisely repair damaged nerve cells, aiming to fundamentally terminate or delay Parkinson's disease. disease (PD) progression. The current progress of this project is in the first echelon in the world. It is safer and has a short preparation cycle. It can be used in autologous and allogeneic transplantation. In March 2022, the company's GMP-like cell product production workshop built in Beijing Zhongguancun Life Science Park was officially put into use, and research work related to the National Food and Drug Administration's drug clinical trial application (i.e. IND application) was carried out. On July 18, 2023, the world's first neurosurgery using iNSC-DAP (induced neural stem cell-derived dopaminergic neural precursor cells) autologous cell transplantation to treat Parkinson's disease was successfully completed at Xuanwu Hospital of Capital Medical University. The 12-month follow-up showed good safety and effectiveness.

With the wisdom of science , and the heart of benevolence, cure the root causes of diseases.